INVION LIMITED — Capital/Financing Update 2021

Nov 22, 2021

==> picture [146 x 53] intentionally omitted <==

ASX Announcement 23 November 2021

Cancellation of options

Invion Limited (ASX:IVX) (“Invion” or the “Company”) advises that the options set out in the Appendix 3G released to the ASX on 22 November 2021 were issued on incorrect terms due to an administrative error and accordingly have been cancelled.

--ENDS--

This announcement is authorised for release to the market by the Company Secretary of Invion Limited.

Investor and Media enquiries:

Thian Chew (Chairman) Brendon Lau (Investor & Media Relations) T: +61 3 9692 7222 T: +61 409 341 613 E: investor@inviongroup.com E: brendon@vantagepointpartners.com.au

About Invion

Invion is a life-science company that is leading the global research and development of PhotosoftTM technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the PhotosoftTM technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by the Board of Invion Limited. For further information please contact investor@inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.

Invion Limited ABN 76 094 730 417 Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia P: +61 3 9692 7222 W: www.inviongroup.com